Khorasanchi Adam, Wu Richard, Kendra Kari, Verschraegen Claire
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Cancers (Basel). 2022 Oct 29;14(21):5325. doi: 10.3390/cancers14215325.
Cutaneous squamous cell carcinoma (CSCC) is the second most common non-melanoma skin cancer. A majority of patients present with localized disease, but some can present with locally advanced or metastatic disease. Most of these advanced cases occur in the anatomical head and neck region and are associated with more aggressive disease, necessitating prompt and effective treatment. Prior to the emergence of immunotherapy, systemic treatment options were limited to platinum-based chemotherapy and salvaged with targeted epidermal growth factor therapy. These therapies were associated with poor efficacy and increased toxicity in an often frail, older population. Immunotherapy has dramatically improved outcomes in this patient population due to its favorable side effect profile, durable treatment response, and improved overall outcomes. In this review, an overview of the recent advances of immunotherapy in the management of CSCC in the anatomical head and neck region is provided, with a focus on advanced presentations.
皮肤鳞状细胞癌（CSCC）是第二常见的非黑色素瘤皮肤癌。大多数患者表现为局限性疾病，但有些患者可能表现为局部晚期或转移性疾病。这些晚期病例大多发生在头颈部解剖区域，且与侵袭性更强的疾病相关，需要及时有效的治疗。在免疫疗法出现之前，全身治疗方案仅限于铂类化疗，并辅以靶向表皮生长因子疗法。这些疗法在通常身体虚弱的老年人群中疗效不佳且毒性增加。免疫疗法因其良好的副作用特征、持久的治疗反应和改善的总体预后，显著改善了该患者群体的治疗结果。在本综述中，提供了免疫疗法在头颈部解剖区域CSCC治疗中的最新进展概述，重点是晚期表现。
